Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT-112 in Subjects With Thymoma and Thymic Carcinoma
NCT05104736Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Imifoplatin in thymoma, thymic carcinoma (TC), sponsored by National Cancer Institute. Started Apr 2022; status: recruiting.
02
Drugs
Imifoplatin
03
Conditions
thymomathymic carcinoma (TC)
Beyond the preview
Go deeper on NCT05104736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05104736.